A Study of Resveratrol as Treatment for Friedreich Ataxia
NCT ID: NCT01339884
Last Updated: 2014-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
27 participants
INTERVENTIONAL
2011-04-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Micronised Resveratrol as a Treatment for Friedreich Ataxia
NCT03933163
Iron-Chelating Therapy and Friedreich Ataxia
NCT00224640
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
NCT04921930
An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
NCT01921868
Coronary Artery Disease in Patients With Friedreich's Ataxia
NCT04649866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resveratrol, 1g daily
15 participants will receive resveratrol 1g daily
Resveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Resveratrol, 5g daily
15 participants will receive resveratrol, 5g daily
Resveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Functional stage on the Ataxia subscale of the FARS of 1 or higher
Exclusion Criteria
* Active arrythmias or significant cardiac insufficiency
* Use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrolment
* Use of amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Friedreich's Ataxia Research Alliance
OTHER
Murdoch Childrens Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Martin Delatycki
Prof Martin Delatycki
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Delatycki, MBBS PhD
Role: PRINCIPAL_INVESTIGATOR
Murdoch Childrens Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Monash Medical Centre, Southern Health
Clayton, Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10358B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.